Table 2 Correlation between poorly differentiated clusters and other clinicopathological characteristics
From: Prognostic value of poorly differentiated clusters in invasive breast cancer
Variable | Poorly differentiated clusters | P | ||
|---|---|---|---|---|
G1 (%) | G2 (%) | G3 (%) | ||
Age | ||||
40 or younger | 3 (7.3%) | 11 (18.3%) | 11 (24.4%) | 0.103 |
>40 | 38 (92.7%) | 49 (81.7%) | 34 (75.6%) | |
T stage | ||||
T1 | 8 (19.5%) | 10 (16.7%) | 6 (13.3%) | 0.779 |
T2 | 30 (73.2%) | 43 (71.7%) | 32 (71.1%) | |
T3 | 3 (7.3%) | 7 (11.6%) | 7 (15.6%) | |
N stage | ||||
N0 | 30 (73.2%) | 29 (78.3%) | 11 (24.4%) | <0.001* |
N1 | 8 (19.5%) | 20 (33.3%) | 16 (35.6%) | |
N2 or 3 | 3 (7.3%) | 11 (18.3%) | 18 (40.0%) | |
Grade | ||||
G1 | 3 (7.3%) | 4 (6.7%) | 0 (0.0%) | 0.134 |
G2 | 25 (61.0%) | 42 (70.0%) | 35 (77.8%) | |
G3 | 13 (31.7%) | 14 (23.3%) | 10 (22.2%) | |
Lymphovascular invasion | ||||
Negative | 36 (87.8%) | 48 (80.0%) | 27 (60.0%) | 0.007* |
Positive | 5 (12.2%) | 12 (20.0%) | 18 (40.0%) | |
Estrogen receptor/progesterone receptor expression | ||||
Negative | 20 (48.8%) | 24 (40.0%) | 19 (42.2%) | 0.674 |
Positive | 21 (51.2%) | 36 (60.0%) | 26 (57.8%) | |
HER-2 overexpression | ||||
Negative | 38 (92.7%) | 51 (85.0%) | 29 (64.4%) | 0.003* |
Positive | 3 (7.3%) | 9 (15.0%) | 16 (35.6%) | |
Triple negative status | ||||
No | 23 (56.1%) | 36 (60.0%) | 30 (66.7%) | 0.593 |
Yes | 18 (43.9%) | 24 (40.0%) | 15 (33.3%) | |
Tumor budding | ||||
G1 | 27 (65.9%) | 27 (45.0%) | 9 (20.0%) | <0.001* |
G2 | 11 (26.8%) | 24 (40.0%) | 20 (44.4%) | |
G3 | 3 (7.3%) | 9 (15.0%) | 16 (35.6%) | |
Relapse | ||||
No | 37 (90.2%) | 49 (81.7%) | 16 (35.6%) | <0.001* |
Yes | 4 (9.8%) | 11 (18.3%) | 29 (64.4%) | |
Death | ||||
No | 38 (92.7%) | 51 (85.0%) | 25 (55.6%) | <0.001* |
Yes | 3 (7.3%) | 9 (15.0%) | 20 (44.4%) | |
Total 146 | 41 | 60 | 45 | |